The firm began a Phase II study of evorpacept in HER2-positive breast cancer patients and began testing a higher dose of ALX2004 in a separate Phase I trial.
The therapy, A2B543, will be added as an arm to the ongoing Phase I/II EVEREST-2 trial, which is testing CAR T-cell products developed using A2's Tmod platform. According to A2, the Tmod platform ...
NEW YORK – Sarepta Therapeutics on Wednesday said it submitted an application to regulators in New Zealand, seeking to begin a first-in-human trial of SRP-1005, the siRNA drug it's developing for ...
Lexeo says the collaboration will accelerate the development of an unnamed preclinical cardiac gene therapy target.
CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...
The companies struck a multi-year strategic collaboration, under which GSK will have access to Helix's GenoSphere cohorts.
The deal brings Dark Blue's preclinical oncology products, including an MLLT1/3-targeted agent for leukemias, into Amgen's portfolio.
The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.
The collaboration will support development of Ascidian's RNA exon editor therapy, ACDN-01, for treating the rare genetic eye disease.
Axovia Therapeutics Nabs $1.1M Grant to Advance BBS1 Vision Loss Gene Therapy Toward Clinical Trials
With this new grant, nonprofit A Race Against Blindness has provided a total of $5.1 million to advance AXV-101.
Cartography will be eligible to receive more than $850 million, if Pfizer exercises all options and brings a drug from the collaboration to the market.
The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback